Privium Fund Management B.V. Makes New $698,000 Investment in Sarepta Therapeutics, Inc. $SRPT

Key Points

• Privium Fund Management B.V. has invested $698,000 in Sarepta Therapeutics by purchasing 39,400 shares in the second quarter.
• Analysts have mixed ratings on Sarepta, with the stock receiving eight "Buy" ratings, fourteen "Hold" ratings, and seven "Sell" ratings.
• Sarepta Therapeutics reported earnings of $2.02 per share, significantly surpassing analysts' expectations of $0.89, with a revenue increase of 68.4% year-over-year.

Privium Fund Management B.V. bought a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 39,400 shares of the biotechnology company's stock, valued at approximately $698,000.

Several other large investors have also modified their holdings of the stock. Janney Montgomery Scott LLC acquired a new position in Sarepta Therapeutics in the first quarter worth about $821,000. State of Alaska Department of Revenue lifted its holdings in Sarepta Therapeutics by 2.6% during the 1st quarter. State of Alaska Department of Revenue now owns 11,175 shares of the biotechnology company's stock worth $713,000 after buying an additional 285 shares during the last quarter. Center for Financial Planning Inc. bought a new position in Sarepta Therapeutics during the 1st quarter worth approximately $31,000. Cambridge Investment Research Advisors Inc. grew its position in shares of Sarepta Therapeutics by 5.9% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 6,387 shares of the biotechnology company's stock worth $408,000 after acquiring an additional 358 shares in the last quarter. Finally, Sava Infond d.o.o. increased its holdings in shares of Sarepta Therapeutics by 50.0% in the 1st quarter. Sava Infond d.o.o. now owns 4,500 shares of the biotechnology company's stock valued at $287,000 after acquiring an additional 1,500 shares during the last quarter. Institutional investors own 86.68% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on SRPT shares. Robert W. Baird raised their price objective on Sarepta Therapeutics from $30.00 to $35.00 and gave the stock an "outperform" rating in a research note on Thursday, July 17th. Mizuho restated a "neutral" rating and issued a $14.00 price target (down from $40.00) on shares of Sarepta Therapeutics in a research report on Monday, July 21st. HC Wainwright reaffirmed a "sell" rating on shares of Sarepta Therapeutics in a research report on Monday, August 25th. Jefferies Financial Group cut their target price on shares of Sarepta Therapeutics from $40.00 to $35.00 and set a "buy" rating on the stock in a report on Thursday, July 24th. Finally, The Goldman Sachs Group upped their target price on Sarepta Therapeutics to $19.00 and gave the company a "neutral" rating in a report on Thursday, August 7th. Eight research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and seven have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $34.42.

Sarepta Therapeutics Stock Performance

SRPT opened at $23.05 on Tuesday. The company has a current ratio of 2.89, a quick ratio of 1.81 and a debt-to-equity ratio of 0.84. The business's 50 day moving average is $19.72 and its 200-day moving average is $28.79. The stock has a market cap of $2.25 billion, a PE ratio of -26.49 and a beta of 0.51. Sarepta Therapeutics, Inc. has a twelve month low of $10.41 and a twelve month high of $138.81.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.89 by $1.13. The business had revenue of $611.09 million during the quarter, compared to analyst estimates of $530.66 million. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.The business's revenue for the quarter was up 68.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.07 EPS. On average, analysts predict that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.